Lacerta Therapeutics
Dr. Heldermon is an Associate Professor of Medicine at the University of Florida. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He has extensive preclinical data for the use of AAV to treat Sanfilippo syndrome B.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.